Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Edgewater Wireless Systems Inc
Integral Ad Science Holding Corp. - Common Stock
micromobility.com Inc. - Class A Common Stock
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Belite Bio, Inc - American Depositary Shares
(NQ:
BLTE
)
127.38
-23.64 (-15.65%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Belite Bio, Inc - American Depositary Shares
< Previous
1
2
3
4
5
Next >
Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA
Today 8:00 EST
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
November 12, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
November 05, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
October 19, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
October 14, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
October 01, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
September 28, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
September 08, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in Four Upcoming Investor Conferences
September 01, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Virtual Commercial Day on September 2, 2026
August 24, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
August 21, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
August 12, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
August 11, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
August 06, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
July 20, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
July 15, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
July 06, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
July 06, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
June 12, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 02, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
May 20, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
May 18, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
May 15, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
May 13, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
April 29, 2026
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
April 27, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
April 23, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio to Participate in Four Upcoming Investor Conferences
April 23, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
April 22, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
April 21, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1